AbbVie (ABBV): Officer exercised options on 16K shares
Jeffrey Ryan Stewart, Officer at AbbVie, reported an option exercise of 16K shares.
- 16K
- Shares · @ $114.36
- Traded
- Nov 9, 2026
- Filed
- Nov 12, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 14, 2026CongressDisclosed sale of ABBV — reported range $15,001 - $50,000
- Sep 25, 2026FDAFDA drug approval: Juvmo
- Oct 5, 2026Company filing · Form 8-K · ResultsReported its results
- Oct 14, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 14, 2026, AbbVie Inc. (“AbbVie”) expanded the size of its Board of Directors (the “Board”) from twelve directors to thirteen directors and appointed Dr. John M. Carethers as a Class II director.”
- Oct 23, 2026FDAFDA drug approval: Skyrizi
- Oct 28, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On October 28, 2026, Jennifer L. Davis, a Class II director of AbbVie Inc. (“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc. Her resignation as a director is not the result of any dispute or disagreement with AbbVie on any matter relating to…”
- Oct 30, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 9, 2026Insider · Their largest sale since 2020Officer sold ~$11.9M of ABBV shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for AbbVie
For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.
Other recent filings by Jeffrey Ryan Stewart, EVP, CHIEF COMMERCIAL OFFICER
- SEC Form 4 at AbbVie (ABBV)Nov 12, 2026
- SEC Form 4 at AbbVie (ABBV)Apr 2, 2025
- SEC Form 4 at AbbVie (ABBV)Apr 2, 2025
The full history of Jeffrey Ryan Stewart, EVP, CHIEF COMMERCIAL OFFICER is on the profile page.
How this filing works
Explore the data
Other disclosures at AbbVie
- SEC Form 4Nov 12, 2026
- SEC Form 144Nov 9, 2026
- House Clerk periodic transaction reportSep 18, 2026
- SEC Form 13F-HRAug 26, 2026
- SEC Form 13F-HRAug 25, 2026
- SEC Form 4Aug 18, 2026
Everything OQRO holds on this company is on its ABBV page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
